Our Team

Directors and Officers

Tyler Powell

Tyler Powell

Chief Executive Officer & Director

Tyler Powell is an experienced entrepreneur with over 15 years of experience in the financial services sector. As a leader, Tyler identifies areas with substantial unmet need and builds collaborative teams with diverse experience that believe in the mission.

Tyler has deep expertise in venture capital, initial public offerings, secondary financings, mergers and acquisitions, public vehicles, and operations as well as in media and investor relations. While running a financial services consulting company for a decade, Tyler supported promising companies with infusions of capital, management and restructuring to maximize the value of their core business.

Connect with Tyler on LinkedIn here.

Arron Victory

Arron Victory

Chief Strategy Officer & Director

Arron Victory is a purpose-built entrepreneur, corporate strategy leader, Canadian Armed Forces Veteran and advocate with robust experience in health care, emerging therapeutics, and community engagement. From commanding up to thirty heroes during his time in the military, to building multiple businesses in nascent industries like cannabis and psychedelics, he leads with passion, listens and partners with patients and stakeholders, and thrives when there isn’t a playbook.

Arron is also an Ambassador for Veteran advocacy group, Wounded Warriors Canada, Board Member of the Heroic Hearts Project, a charity providing access to psychedelic therapies for Veterans, and an Advisory Board Member for the Chronic Pain Centre of Excellence, a research centre improving the understanding of Veteran-specific chronic pain and how best to manage it.

Connect with Arron on LinkedIn here.

Dr. Orion Lekos

Dr. Orion Lekos

Chief Science Officer & Director

Dr. Lekos is an industry-leading green entrepreneur and engineer, specializing in the extraction of valuable phytochemicals from plants, renewable energy, water, biomass derived chemicals, and micro-organisms.

With a PhD in Bioengineering and a master’s degree in environmental chemistry, Dr. Lekos has led global clinical trials while being instrumental in the development & design of the extractions and formulations for a top three global cannabis company. He also served as the Chief Science Officer of a biotechnology company developing poppy genetics to produce non-addictive opiate alkaloids.

Dr. Lekos also has robust experience in Technology Commercialization, Environmental Management, Life Cycle Analysis, Industrial Plant Design, Plant Commissioning, Green Chemical Design, and Good Manufacturing Practices.

Connect with Dr. Lekos on LinkedIn here.

Dr. Peter Tomlinson

Dr. Peter Tomlinson, MBA

Chief Clinical Officer

Dr. Tomlinson is a clinical development expert specializing in clinical trial and pharmaceutical commercialization strategy and four decades of health and pharmaceutical experience. With a PhD in analytical chemistry, as President of AlthoTech Consulting, Dr. Tomlinson has helped over 25 biotechnology and pharmaceutical companies develop and execute effective clinical trial strategies, Chemistry Manufacturing Controls (CMCs), Good Manufacturing Practices (GMP), and other aspects of new product development.

He has worked across traditional and emerging healthcare sectors, partnering and working with leading companies such as GSK, Tilray, Aegera, Purgenesis, Ultragenyx, Sharp & Taro.

Connect with Dr. Tomlinson on LinkedIn here.

Sam Isaac

Sam Isaac

Chief Financial Officer

As a chartered accountant with a depth of experience in private equity firms, public companies’ start-ups and one of the big four accounting firms, Sam is a results-driven finance and operations executive with proven success across multiple industries.

He brings 15 years of international capital markets experience, having worked with multiple publicly traded companies, raised over $100 million in equity capital and supported go-public strategies, private placements and prospectus offerings.

He also specializes in heavily regulated sectors, having managed financial priorities in licensing acquisition for cannabis R&D, and worked with multiple organizations in technology and energy sectors.

Dr. Enrique Carrazana

Dr. Enrique Carrazana


Dr. Enrique Carrazana is a Harvard-trained, board-certified neurologist with over 25 years of experience in drug development and the pharmaceutical industry. He is a member of the board of directors of CND Life Sciences, Hawaii Biotech, and the American Society for Experimental Neurotherapeutics.

He currently serves as the Chief Medical Officer for Neurelis, Inc., where he is responsible for the management of the drug development and safety programs. Previously, he was the Chief Medical Officer of Acorda Therapeutics. Dr. Carrazana also held various medical leadership roles at Novartis, where his last role was Vice President, Global Head Development Established Medicines Franchise, based in Basel, Switzerland.

He was Director of the Epilepsy Center of Excellence at the Miami Veterans’ Administration (VA) Hospital and Associate Professor of Neurology at the University of Miami, Miller School of Medicine. He has presented and published a wide range of research on various neurology topics.

Dr. Carrazana received his medical degree from Harvard Medical School and completed his residency in neurology and fellowship in neurophysiology at the Harvard Longwood Neurology Program and is a fellow of the American Epilepsy Society.

Tom McGaugh

Tom McGaugh


As President & CEO of Greenpoint Associates, Tom provides nearly two decades of financial accounting excellence and experience supporting start-ups, small businesses, and publicly traded companies across the globe with IPO readiness services and financial accounting support.

He has substantial experience in emerging therapeutic markets, as the former Vice President of Finance for Tilray, helping them make history by being the first cannabis company to debut on a major U.S. stock exchange. He was instrumental in getting the company ready for its IPO and proudly flew to New York City to ring the bell in July of 2018.

Jim  Pakulis

Jim Pakulis


Jim is a seasoned executive leader and investor with over a decade of experience in emerging industries. He specializes in companies operating within sectors at the cusp of market development with potential for robust growth, focusing on lean and conservative capital structures and guiding them from ideation through to the point of execution.

Jim has experience as CEO & Director of numerous successful public & private companies across North America, raising millions in conjunction. This includes his role as the CEO of WeedMaps, taking them public in 2010 to become one of the first publicly traded cannabis companies in the US. He is the former President of a technology company focused on unique and metered dosing delivery systems of cannabis, and was founder and CEO of TransCanna, a North American cannabis company.

For Apex Labs, Jim offers his extensive sector and corporate knowledge to the executive team, along with a wide network of key funding opportunities.

Strategic Advisors

  • Raashid NaikPharmacist & Senior Director at Shopper’s Drug Mart
  • Greg RutherfordGlobal Commercialization
  • Dr. Emmanouil RampakakisClinical Trial Protocols Specialist
  • Dana NohynekClinical Development and Regulatory Affairs
  • Dr. Kevin LutzVeteran and PTSD Clinician
  • Dr. David WoodIntellectual Property and Regulatory Attorney
  • Dr. Franklin KingPsychiatrist, Professor & Experienced Psychedelic Clinical Investigator
  • Dr. Bal KangDrug Design and Assay Development
  • Bob CrossCapital Markets and Corporate Structure
  • Victoria DekkerPublic Relations
  • Max Monahan-EllisonCorporate Affairs

Partners & Associates

Changemark Research

Site Operations & Regulatory.


Dealer’s licence laboratory.

DLA Piper (Canada) LLP

Leading global legal firm managing the corporate, securities and go public path for APEX.


GMP certification expert consulting outfit.

R-Group Law

Law firm handling APEX’s Canadian Regulatory and IP.


Canada's leading non-profit advocating for nation-wide psychedelic medical access.

JSS Medical Research

Clinical Research Organization (CRO) handling clinical trials and protocols.